TEVA•benzinga•
Piper Sandler Downgrades Teva Pharmaceutical Indus to Underweight, Lowers Price Target to $7
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 4, 2022 by benzinga